Investing in Quantum-Si carries substantial risks inherent to micro-cap biotechnology and early-stage life sciences firms. Primary risks include ongoing operating losses, continuous cash burn rates requiring potential future capital raises or share dilutions, slower-than-anticipated commercial adoption rates for new laboratory instruments, and heightened share price volatility typical of small-cap equities navigating competitive healthcare markets.